Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 147

Similar articles for PubMed (Select 21619455)

1.

Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.

Amonkar MM, Chastek B, Samant N, Teitelbaum A.

J Med Econ. 2011;14(4):421-32. doi: 10.3111/13696998.2011.584096. Epub 2011 May 27.

PMID:
21619455
2.

Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK.

Kim K, Amonkar MM, Högberg D, Kasteng F.

Head Neck Oncol. 2011 Oct 28;3:47. doi: 10.1186/1758-3284-3-47.

3.

Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.

Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA, Hatfield A, Cortes J.

Pharmacoeconomics. 2007;25(6):481-96.

PMID:
17523753
4.

Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan.

Garris C, Jhingran P, Bass D, Engel-Nitz NM, Riedel A, Dennis G.

J Med Econ. 2013;16(5):667-77. doi: 10.3111/13696998.2013.778270. Epub 2013 Mar 11.

PMID:
23425294
5.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
6.

Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck.

Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J.

Arch Otolaryngol Head Neck Surg. 2009 Jun;135(6):582-8. doi: 10.1001/archoto.2009.46.

PMID:
19528407
7.

Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.

Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, Wacha J, Bayouth JE, Funk GF, Smith RB, Graham SM, Chang K, Hoffman HT.

Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):410-21.

PMID:
16168834
8.

Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.

Chastek B, Kulakodlu M, Valluri S, Seal B.

Postgrad Med. 2013 Mar;125(2):73-82. doi: 10.3810/pgm.2013.03.2642.

PMID:
23816773
9.

Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.

Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.

Ann Pharmacother. 2007 Nov;41(11):1761-9. Epub 2007 Sep 25.

PMID:
17895328
10.

The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data.

Lang K, Menzin J, Earle CC, Jacobson J, Hsu MA.

Arch Otolaryngol Head Neck Surg. 2004 Nov;130(11):1269-75.

PMID:
15545580
11.

Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.

Pelletier EM, Shim B, Ben-Joseph R, Caro JJ.

Pharmacoeconomics. 2009;27(6):479-90. doi: 10.2165/00019053-200927060-00004.

PMID:
19640011
12.

Overlap of anxiety and depression in a managed care population: Prevalence and association with resource utilization.

McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R.

J Clin Psychiatry. 2006 Aug;67(8):1187-93.

PMID:
16965195
13.

Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.

Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J.

Clin Ther. 2009 Nov;31(11):2653-64. doi: 10.1016/j.clinthera.2009.11.032.

PMID:
20110008
14.

Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.

Angalakuditi M, Edgell E, Beardsworth A, Buysman E, Bancroft T.

J Med Econ. 2010;13(3):393-402. doi: 10.3111/13696998.2010.496694.

PMID:
20608882
15.

The economic burden of lung cancer and the associated costs of treatment failure in the United States.

Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH.

Lung Cancer. 2005 Nov;50(2):143-54. Epub 2005 Aug 19.

PMID:
16112249
16.

Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.

Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME.

Appl Health Econ Health Policy. 2008;6(2-3):103-12. doi: 10.2165/00148365-200806020-00003.

PMID:
19231904
17.

Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH.

Cardiovasc Diabetol. 2009 Sep 26;8:53. doi: 10.1186/1475-2840-8-53.

18.

Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

Copher R, Cerulli A, Watkins A, Laura Monsalvo M.

J Med Econ. 2012;15(5):947-55. doi: 10.3111/13696998.2012.690801. Epub 2012 May 22.

PMID:
22554140
19.

Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.

Pelletier EM, Shim B, Goodman S, Amonkar MM.

Breast Cancer Res Treat. 2008 Mar;108(2):297-305. Epub 2007 Jun 19.

PMID:
17577662
20.

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM.

Pharmacoeconomics. 2007;25(2):155-69.

PMID:
17249857
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk